Therefore, relevant research about clarifying the mechanism and finding a predictive marker for the gp96 tumor vaccine must be performed to improve the holistic outcome of the gp96 tumor vaccine as a glioma treatment. This evidence concerns the gene HSP90B1 and central nervous system cancer.